β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy

Journal of Endocrinology

Volumn 213, Issue 2, 2012, Pages 183-191

  Antonelli, Alessandro ^a   Ferrari, Silvia Martina ^a   Frascerra, Silvia ^a   Ruffilli, Ilaria ^a   Pupilli, Cinzia ^b   Bernini, Giampaolo ^a   Sellari Franceschini, Stefano ^a   Gelmini, Stefania ^c   Ferrannini, Ele ^a   Fallahi, Poupak ^a  

^a UNIVERSITY OF PISA   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CYTOKINE RELEASE; ENDOCRINE OPHTHALMOPATHY; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOMODULATION; PRIORITY JOURNAL; PROADIPOCYTE;

CELLS, CULTURED; CHEMOKINE CCL2; CHEMOKINE CXCL10; FENOFIBRATE; FIBROBLASTS; GRAVES OPHTHALMOPATHY; HUMANS; INTERFERON-GAMMA; PPAR ALPHA; PPAR GAMMA; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862084228     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-11-0488     Document Type: Article

References (40)

1. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A, Ferrannini E & Serio M 2004 High levels of circulating CXCL10 are associated with chronic autoimmune thyroiditis and hypothyroidism. Journal of Clinical Endocrinology and Metabolism 89 5496-5499.
2. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Romagnani P, Grosso M, Ferrannini E & Serio M 2006a Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. European Journal of Endocrinology 154 651-658.
3. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M & Miccoli P 2006b Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. British Journal of Surgery 93 1226-1231.
4. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, Serio M & Ferrannini E 2006c Interferon-gamma-inducible alphachemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. Journal of Clinical Endocrinology and Metabolism 91 614-620.
5. Antonelli A, Rotondi M, Fallahi P, Grosso M, Boni G, Ferrari SM, Romagnani P, Serio M, Mariani G & Ferrannini E 2007 Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. Journal of Clinical Endocrinology and Metabolism 92 1485-1490.
6. Antonelli A, FerriC, Fallahi P, Ferrari SM, GiuggioliD, Colaci M, Manfredi A, Frascerra S, Franzoni F, Galetta F et al. 2008 CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis - a longitudinal study. Rheumatology 47 45-49.
7. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Santini E, Franceschini SS & Ferrannini E 2009a Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. Journal of Clinical Endocrinology and Metabolism 94 1803-1809.
8. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Piaggi S, Gelmini S, Lupi C, Minuto M, Berti P, Benvenga S et al. 2009b Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists. Endocrine-Related Cancer 16 1299-1311.
9. Antonelli A, Ferrari SM, Frascerra S, Pupilli C, Mancusi C, Metelli MR, Orlando C, Ferrannini E & Fallahi P 2010 CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptoralpha agonists secretion in Graves' and normal thyrocytes. Journal of Clinical Endocrinology and Metabolism 95 E413-E420.
10. Antonelli A, Ferrari SM, Frascerra S, Ruffilli I, Gelmini S, Minuto M, Pupilli C, Miccoli P, Sellari-Franceschini S et al. 2012 Peroxisome proliferator-activated receptor-a agonists modulate CXCL9 and CXCL11 chemokines in Graves' ophthalmopathy fibroblasts and preadipocytes. Molecular and Cellular Endocrinology 349 255-261.
11. Bahn RS, Gorman CA, Johnson CM & Smith TJ 1989 Presence of antibodies in the sera of patients with Graves' disease recognizing a 23 kilodalton fibroblast protein. Journal of Clinical Endocrinology and Metabolism 69 622-662.
12. Chen K, Wei Y, Alter A, Sharp GC & Braley-Mullen H 2005 Chemokine expression during development of fibrosis versus resolution in a murine model of granulomatous experimental autoimmune thyroiditis. Journal of Leukocyte Biology 78 716-724.
13. Chen MH, Liao SL, Chang TC & Chuang LM 2008 Role of macrophage infiltration in the orbital fat of patients with Graves' ophthalmopathy. Clinical Endocrinology 69 332-337.
14. Cuzzocrea S, Di Paola R, Mazzon E, Genovese T, Muiá C, Centorrino T & Caputi AP 2004 Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-alpha) in the development of inflammatory bowel disease in mice. Laboratory Investigation 84 1643-1654.
15. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, & Staels B 1999 Peroxisomeproliferatoractivated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. Journal of Biological Chemistry 274 32048-32054.
16. Delerive P, Gervois P, Fruchart JC & Staels B 2000 Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. Journal of Biological Chemistry 275 36703-36707.
17. Dragomir E, Tircol M, Manduteanu I, Voinea M & Simionescu M 2006 Aspirin and PPAR-alpha activators inhibit monocyte chemoattractant protein-1 expression induced by high glucose concentration in human endothelial cells. Vascular Pharmacology 44 440-449.
18. Garciá-López MA, Sancho D, Sánchez-Madrid F & Marazuela M 2001 Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3C lymphocytes. Journal of Clinical Endocrinology and Metabolism 86 5008-5016.
19. Gervois P, Kleemann R, Pilon A, Percevault F, Koenig W, Staels B & Kooistra T 2004 Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. Journal of Biological Chemistry 279 16154-16160.
20. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C & Kelman JA 2010 Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. Journal of the American Medical Association 304 411-418.
21. Hwang CJ, Afifiyan N, Sand D, Naik V, Said J, Pollock SJ, Chen B, Phipps RP, Goldberg RA, Smith TJ et al. 2009 Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1. Investigative Ophthalmology and Visual Science 50 2262-2268.
22. Lee SM, Yung WH, Chen L & Chow BK 2005 Expression and spatial distribution of secretin and secretin receptor in human cerebellum. Neuroreport 16 219-222.
23. Lee JW, Bajwa PJ, Carson MJ, Jeske DR, Cong Y, Elson CO, Lytle C & Straus DS 2007 Fenofibrate represses interleukin-17 and interferongamma expression and improves colitis in interleukin-10 deficient mice. Gastroenterology 133 108-123.
24. Lombardi A, Cantini G, Piscitelli E, Gelmini S, Francalanci M, MelloT, Ceni E, Varano G, Forti G, RotondiM et al. 2008 A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-gamma inflammatory effects in human endothelial cells. Arteriosclerosis, Thrombosis, andVascular Biology 28 718-724.
25. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A & Piomelli D 2005 The nuclear receptor peroxisome proliferator activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Molecular Pharmacology 67 15-19.
26. Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, Chavis JA, Diab A, Drew PD & Racke MK 2004 Peroxisome proliferatoractivated receptor alpha agonists as therapy for autoimmune disease. Journal of Immunology 172 5790-5798.
27. Majumder S, Zhou LZ, Chaturvedi P, BabcockG, Aras S& Ransohoff RM 1998 p48/STAT-1 alpha-containing complexes play a predominant role in induction of IFN-gamma-inducible protein, 10 kDa (IP-10) by IFN-gamma alone or in synergy with TNF-alpha. Journal of Immunology 161 4736-4744.
28. Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, Libby P, Plutzky J & Luster AD 2000 Peroxisome proliferator-activated receptorgamma activators inhibit IFN-gamma-induced expression of the T cellactive CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. Journal of Immunology 164 6503-6508.
29. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S et al. 2006 International union of pharmacology LXI peroxisome proliferator-activator receptors. Pharmacological Reviews 58 726-741.
30. Moynihan R 2011 European drug agency extends review of safety of pioglitazone. BMJ 342 d4105.
31. Nie M, Corbett L, Knox AJ&Pang L 2005Differential regulation of chemokine expression by peroxisome proliferator-activated receptor gamma agonists: interactions with glucocorticoids and beta2-agonists. Journal of Biological Chemistry 280 2550-2561.
32. Okamoto H, Iwamoto T, Kotake S, Momohara S, Yamanaka H & Kamatani N 2005 Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clinical and Experimental Rheumatology 23 323-330.
33. Oliveira AC, Bertollo CM, Rocha LT, Nascimento EB Jr, Costa KA & Coelho MM 2007 Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPARalpha, and pioglitazone, an agonist of PPARgamma. European Journal of Pharmacology 561 194-201.
34. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG & Glass CK 2005 A SUMOylationdependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437 759-763.
35. Pasquali D, Pierantoni GM, Fusco A, Staibano S, Colantuoni V, De Bellis A, Bellastella A & Sinisi AA 2004 Fenofibrate increases the expression of high mobility group AT-hook 2 (HMGA2) gene and induces adipocyte differentiation of orbital fibroblasts from Graves' ophthalmopathy. Journal of Molecular Endocrinology 33 133-143.
36. Romagnani S 1997 The Th1/Th2 paradigm. Immunology Today 18 263-266.
37. Schaefer KL, Denevich S, Ma C, Cooley SR, Nakajima A, Wada K, Schlezinger J, Sherr D & Saubermann LJ 2005 Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptorgamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflammatory Bowel Diseases 11 244-252.
38. Spencer NF, Poynter ME, Im SY & Daynes RA 1997 Constitutive activation of NF-kappa B in an animal model of aging. International Immunology 9 1581-1588.
39. Struyf S, Van Collie E, Paemen L, Put W, Lenaerts JP, Proost P, Opdenakker G & Van Damme J 1998 Synergistic induction of MCP-1 and -2 by IL-1beta and interferons in fibroblasts and epithelial cells. Journal of Leukocyte Biology 63 364-367.
40. Yamana J, Santos L & Morand E 2009 Enhanced induction of LPS-induced fibroblast MCP-1 by interferon-gamma: involvement of JNK and MAPK phosphatase-1. Cellular Immunology 255 26-32.